Checkpoint Capital L.P. Cytokinetics Inc Transaction History
Checkpoint Capital L.P.
- $196 Billion
- Q4 2024
A detailed history of Checkpoint Capital L.P. transactions in Cytokinetics Inc stock. As of the latest transaction made, Checkpoint Capital L.P. holds 20,000 shares of CYTK stock, worth $796,200. This represents 0.48% of its overall portfolio holdings.
Number of Shares
20,000
Previous 466,813
95.72%
Holding current value
$796,200
Previous $24.6 Billion
96.18%
% of portfolio
0.48%
Previous 12.23%
Shares
4 transactions
Others Institutions Holding CYTK
# of Institutions
401Shares Held
115MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$584 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$474 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$428 Million0.31% of portfolio
-
State Street Corp Boston, MA6.17MShares$246 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$113 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.75B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...